Abstract:Abstract Background: Metastatic Castration-Resistance Prostate cancer (mCRPC) is a disease state associated with poor survival. Current FDA-approved therapies are non-curative and can only extend mCRPC patient survival by a few months. Therefore, there is an unmet need to improve therapies for patients with advanced disease. Immunotherapy is an effective treatment strategy for a number of cancers but showed limited success in mCRPC patients. Prostate cancer cells exhibit reduced surface expression of major histocompatibility complex (MHC) molecules as an evasive mechanism from cytotoxic CD8+ T-cells. Natural killer (NK) cells are another class of immune cells with anti-tumor characteristics and can target cancer cells independently of MHC expression. Increased NK cell infiltration and activity in prostate cancer has been associated with favorable patient outcomes, but cancer cells have evolved resistance mechanisms against NK cell targeting. We hypothesize that there are druggable pathways that can be exploited to enhance anti-tumor activities of NK cells and improve efficacy of immunotherapies. Methods: To investigate these pathways, we established and characterized an in vitro co-culture system between prostate cancer and NK cells. We conducted the first targeted pool CRISPR screen identifying genes that, when knockout (KO) in prostate cancer cells, enhance killing by NK cells. We validated the screen by individually KO the gene hits. To explore the potential resistance mechanisms conferred by these hits, we performed RNA seq in control and KO cells. Results: Our screen nominated several known ligands of NK cells including CD58 and PVRL2, as well as RNF31 as the top novel target in promoting NK-mediated kill of cancer cells. RNF31 is upregulated in prostate cancer and is part of a druggable linear ubiquitin chain assembly complex (LUBAC). Single sgRNA validation experiments confirmed that RNF31 KO significantly sensitized LNCaP cells to NK92-mediated depletion. Importantly, RNF31 KO did not affect cancer cell proliferation, suggesting that the observed effects are due to the actions of NK cells. We observed that immune response related genes were upregulated in the RNF31 KO cells compare to the wildtype cells. Furthermore, pharmacologic inhibiting RNF31 via LUBAC inhibitor Hopin-8 sensitizes LNCaP cell to NK cell mediated kill. Conclusions: We anticipate that results from this study will yield insights into a novel tumor-intrinsic mechanism of immune evasion in prostate cancer and evaluate the therapeutic potential of targeting this pathway. We hope this work will help identify new therapeutic options or combination treatments that can improve the efficacy of immunotherapy in prostate cancer and significantly extend the lives of patients with advanced prostate cancer. Acknowledgements: This study was supported by the DOD Early Investigator Research Award to TL. Citation Format: Tianyi Liu, Haolong Li, Tony Junjie Hua, Hyunjin Shin, Tanushree Shenoy, Martin Sjoestroem, Arian Lundberg, Luke Gilbert, David Quigley, Alan Ashworth, Lewis Lanier, Felix Feng. Investigation of the ubiquitin ligase RNF31 as a mediator of immune evasion in advanced prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr B031.

Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Regulation of Androgen Receptor Transcriptional Activity and Specificity by RNF6-Induced Ubiquitination

Correction: Functional Domain and Motif Analyses of Androgen Receptor Coregulator ARA70 and Its Differential Expression in Prostate Cancer.

Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells

Leukemia inhibitory factor receptor homodimerization mediated by acetylation of extracellular lysine promotes prostate cancer progression through the PDPK1/AKT/GCN5 axis

UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications

Palmitoylome Profiling Indicates That Androgens Regulate the Palmitoylation of Α‑tubulin in Prostate Cancer‑derived LNCaP Cells and Supernatants

Kat5 And Kat6b Are In Positive Regulation On Cell Proliferation Of Prostate Cancer Through Pi3k-Akt Signaling

The histone H2B ubiquitin ligase RNF40 is required for HER2-driven mammary tumorigenesis

CRISPR Screening Reveals Gleason Score and Castration Resistance Related Oncodriver Ring Finger Protein 19 A (RNF19A) in Prostate Cancer

Abstract 6282: Novel androgen related gene network in prostate cancer cell model

Ubiquitin Ligase RNF20/40 Facilitates Spindle Assembly and Promotes Breast Carcinogenesis Through Stabilizing Motor Protein Eg5

Analysis of the Androgen Receptor-Regulated Lncrna Landscape Identifies a Role for ARLNC1 in Prostate Cancer Progression

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

Nrf1 and Nrf2 Transcription Factors Regulate Androgen Receptor Transactivation in Prostate Cancer Cells

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

Differential Regulation of Androgen Receptor by Pim-1 Kinases Via Phosphorylation-Dependent Recruitment of Distinct Ubiquitin E3 Ligases

LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation

Abstract B031: Investigation of the ubiquitin ligase RNF31 as a mediator of immune evasion in advanced prostate cancer

Abstract 2458: the Androgen Receptor-Regulated Lncrna Landscape Reveals a Role Forarlnc1in Prostate Cancer Progression